The models developed by the pre-therapy 18F-FDG PET/CT radiomic signature and clinical parameters are able to predict MYCN amplification and 1p and 11 aberrations in pediatric NB, thus risk stratification, disease management and guiding personalized malignancy therapy in the clinical practice. Here, MYCN is linked to neuroblastoma.